Johnson & Johnson stock price, JNJ

Johnson & Johnson stock chart:



Johnson & Johnson close price: 123.64

Stock price forecast:

UP TO +0.01%
Target: 123.65

Total forecasts: 90
Reached: 0 (0.00%)

Total Win: 0.00 (0.00%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
909100.00%0.000.00%11,247.02-4.22-0.04%-4.22-0.04%
303100.00%0.000.00%3,832.840.000.00%0.000.00%
141500.00%0.000.00%1,854.600.000.00%0.000.00%
7800.00%0.000.00%989.120.000.00%0.000.00%

Showing 1-10 of 625 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-07-24123.64123.650000-00-00
2017-07-23123.64123.640000-00-00
2017-07-22123.64123.640000-00-00
2017-07-21123.64123.640000-00-00
2017-07-20123.64123.630000-00-00
2017-07-19123.64123.630000-00-00
2017-07-18123.64123.630000-00-00
2017-07-17123.64123.60000-00-00
2017-07-16123.64123.640000-00-00
2017-07-15123.64123.640000-00-00

Johnson & Johnson latest news:


  • 07/21/2017 06:37:02

    Why Credit Suisse Prefers Johnson & Johnson Over Pfizer


  • 07/18/2017 07:58:31

    Johnson & Johnson Shares Slip Following Mixed Earnings


  • 06/22/2017 14:05:02

    Dow, S&P 500 book 3rd straight loss, even as oil and health care rally

    The Dow industrials and the S&P 500 on Thursday logged their third straight finish in the red, despite crude-oil prices gaining after a recent sell-off, and as health-care stocks lured buyers. Still, sharp gains in the health-care sector wasn't enough for the Dow Jones Industrial Average and the S&P 500 index to halt a recent downtrend. The Dow closed little changed but enough for the index to end off 0.1% lower at 21,397, the S&P 500 index [: SPX] closed down, 1 point, or less than 0.1%, at 2,434, while the Nasdaq Composite Index logged a slight gain of less than 0.1% at 6,236. Health-care was the start of the day's action, with the sector, as measured by the exchange-traded Health Care Select Sector SPDR ETF on pace to book its best weekly gain, up 9.3%, since the period ended Nov. 11. A popular biotechnology ETF, the iShares Nasdaq Biotechnology ETF , also was on track for its best weekly gain since November. Those moves came as lawmakers released a draft of the GOP-led, health-care bill that is aimed at repealing and replacing Obamacare. Among companies, health-care names Johnson & Johnson and Merck & Co. Inc. [: MRK] were among the best performers among blue chips. Looking ahead, the Federal Reserve's test of the banking sectors financial health will be released after the close, which could influence trade for banks including Goldman Sachs Group , and J.P. Morgan Chase & Co. .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 06/21/2017 10:39:06

    Missouri sues opioid manufacturers, joining two other U.S. states

    Missouri on Wednesday became the third U.S. state to accuse major drug manufacturers of fraudulently misrepresenting the risks of opioid painkillers now at the center of a national addiction epidemic. Missouri Attorney General Josh Hawley said his office filed a lawsuit in a state court in St. Louis against Purdue Pharma LP, Johnson & Johnson (JNJ) and units of Endo International Plc.

  • 06/20/2017 17:35:17

    Supreme Court ruling threatens massive talc litigation against J&J

    (Reuters) - Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.

  • 06/20/2017 17:13:40

    U.S. Supreme Court ruling threatens massive talc litigation against J&J

    June 20 (Reuters) - Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.

  • 06/15/2017 23:04:18

    BRIEF-Johnson & Johnson announces completion of acquisition of Actelion

    * Johnson & Johnson announces completion of acquisition of Actelion

  • 06/09/2017 09:52:22

    Johnson & Johnson expects to complete of Actelion offer on June 16

    ZURICH, June 9 (Reuters) - Johnson & Johnson said Friday's approval of its proposed acquisition of Swiss biotech company Actelion by the European Commission meant all regulatory approvals required to complete the $30 billion deal have been received.

  • 05/26/2017 14:01:52

    Home Depot, Johnson & Johnson Drag DJIA Lower Friday


  • 05/23/2017 10:01:55

    Alexion stock plummets 9% after top management shake-up

    Alexion Pharmaceuticals Inc. shares dropped 9.2% to $104.89 in very active morning trade Tuesday after the company announced departures of its chief commercial officer, chief financial officer and two executive vice presidents. The company just appointed a new chief executive officer, Ludwig Hantson, in late March, and CFO Dave Anderson started at the company in December. "These changes appear to be the plan of the recently appointed new CEO, Ludwig Hantson, and we believe signal his intention to make a complete break with the company's past leadership," said Leerink analyst Geoffrey Porges, adding that after the shake-up, "none of the management team that built the Soliris business, or presided over the value-destroying Synageva deal in 2015, remain in place...These changes are not a complete surprise, given the signals that have been coming from new CEO, but will alarm many investors given the concern that there may be other 'shoes to drop' in terms of disclosure of additional underlying issues with the core business and operations." Still, Porges reiterated an outperform rating for Alexion. Two executives, CCO Carsten Thiel and Executive Vice President, Chief Human Resources Officer Clare Carmichael, will be leaving the company "to pursue new opportunities" starting June 1, the company said. Thiel will be replaced by Brian Goff, who has worked in biopharma for more than 25 years at companies including Johnson & Johnson and Baxter . CFO Anderson will resign at the end of August and Executive Vice President, Head of Research & Development Martin Mackay will be retiring at the end of this year, the company said, with searches underway for the open positions and a new head of human resources. Alexion shares have dropped 19.8% over the last three months, compared with a 1.5% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/16/2017 16:14:45

    U.S. FDA warns of foot, leg amputations with J&J diabetes drug

    May 16 (Reuters) - Johnson & Johnson is required to add new warnings to its diabetes drug, Invokana, about the risk of foot and leg amputations, the U.S. Food and Drug Administration said on Tuesday.

  • 05/15/2017 09:29:09

    Johnson & Johnson's stock jumps after analyst turns bullish for first time in 4 years

    Shares of Johnson & Johnson jumped 1.9% in midday trade Monday, after J.P. Morgan turned bullish on the health care products company for the first time in 4 years on the belief that the recent weakness in fundamentals is on the verge of bottoming. Analyst Michael Weinstein raised his rating to overweight after being at neutral since April 2013. He listed his stock price target to $140, which is about 11% above current levels, from $133. J&J's stock had fallen 4.1% since the March 15 record close through Friday, with most of the losses coming with the selloff after disappointing first-quarter results on April 18. Weinstein expects the second quarter to be "just as challenging," but said he believes sentiment, which is currently "particularly negative," will begin to turn as fundamentals improve in the second half of the year. "We recognize that this is a notably contrarian call today," Weinstein wrote in a note to clients. "But...once J&J gets the second quarter behind it, [year-over-year comparisons] ease considerably, new products should get approved, and clinical read-outs become potential catalysts for an improving pharma business and a reacceleration of top-line growth." The stock has gained 11% over the past 12 months, while the Dow Jones Industrial Average has rallied 20%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 05/04/2017 19:53:50

    UPDATE 2-J&J ordered to pay $110 million in U.S. talc-powder trial

    May 4 (Reuters) - Johnson & Johnson on Thursday was ordered by a Missouri jury to pay over $110 million to a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.

  • 05/04/2017 18:54:41

    J&J ordered to pay $110 million in U.S. talc-powder trial

    (Reuters) - Johnson & Johnson on Thursday was ordered by a Missouri jury to pay over $110 million to a Virginia woman who says she developed ovarian cancer after decades of using of its talc-based products for feminine hygiene.

  • 04/27/2017 09:05:38

    BRIEF-J&J increase qtrly dividend by 5 pct to $0.84 per share

    * Johnson & johnson announces dividend increase of 5.0 percent

  • More trends:

    Johnson ControlsJCI | Jones EnergyJONE-0.95% | Jones Lang LaSalle IncorporatedJLL | Journal Media GroupJMG | Joy Global Inc.JOY | JP Energy Partners LPJPEP | JPMorgan China Region FundJFC | Jumei International Holding LimitedJMEI | Juniper NetworksJNPR | Jupai Holdings LimitedJP |